AstraZeneca reported that the U.S. Food and Drug Administration has turned down its first submission for a monoclonal antibody injection targeting systemic lupus erythematosus. The company stated that the FDA identified deficiencies in the clinical data package and requested additional analyses of patient subgroups. AstraZeneca is preparing an updated application, incorporating new immunogenicity data from a Phase IIb study of 312 patients and extending follow‐up from 24 to 52 weeks. The firm expects a decision on the resubmission during the first half of 2026 and has allocated $45 million to complete the supplemental trials and regulatory interactions.

In a strategic partnership announced this week, AstraZeneca secured rights to an eight‐program obesity pipeline developed by China’s CSPC Pharmaceutical Group. The agreement grants AstraZeneca exclusive global development and commercialization rights for a once‐monthly injectable peptide targeting ghrelin receptors, currently in Phase I safety studies involving 120 healthy volunteers. CSPC will receive an upfront payment of $75 million and is eligible for up to $300 million in milestone payments tied to Phase II proof‐of‐concept, Phase III initiation and regulatory approvals. This deal underscores AstraZeneca’s plan to expand its cardiovascular, renal and metabolism franchise and adds a potential $2.5 billion in peak annual revenue opportunity by 2030.

On January 30, AstraZeneca began direct trading of its ordinary shares on the New York Stock Exchange, aligning its listing with the London Stock Exchange and Nasdaq Stockholm under a unified structure. The prior American Depositary Receipt program on Nasdaq ceased the same day, while trading of AstraZeneca US Bonds commenced immediately on the NYSE. Company Chair Michel Demaré highlighted that the move opens the largest capital market to a broader U.S. investor base. Last year’s pipeline readouts collectively represent a peak revenue opportunity exceeding $10 billion, and AstraZeneca reiterated its goal of achieving $80 billion in annual revenue and launching 20 new medicines by 2030.